Form 4: Akero Therapeutics CEO Andrew Cheng Sells Shares Under 10b5-1 Trading Plan

Akero Therapeutics' CEO, Andrew Cheng, executed sales of common stock on March 10, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 10, 2025, Andrew Cheng, the President and CEO of Akero Therapeutics, sold shares of the company's common stock.
• The sales were executed under a previously adopted Rule 10b5-1 trading plan dated August 16, 2024.
• A total of 30,000 shares were sold in two separate transactions.
• The first transaction involved the sale of 28,784 shares at a weighted average price of $41.746, with prices ranging from $41.22 to $42.21.
• The second transaction involved the sale of 1,216 shares at a weighted average price of $42.313, with prices ranging from $42.226 to $42.500.
• Following these transactions, Andrew Cheng still beneficially owns 656,062 shares of Akero Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to stock sales by an executive. It doesn't inherently convey positive or negative sentiment, as the sales were pre-planned.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, potentially leading to short-term price fluctuations.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. Rule 10b5-1 plans are frequently used to allow insiders to sell shares in a predetermined manner, avoiding accusations of trading on non-public information.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders due to potential short-term price fluctuations.

Key Dates